Oncology Specialist France - Dr. Idriss TROUSSIER

 
2015-present    Medical Doctor, a specialist in radiation oncology
2017-present    Head of clinic radiation oncology of university hospital of Geneva  / Lausanne
22015 –2017  Head of clinic radiation oncology, university hospital Pitié-Salpêtrière, Public assistance of Paris hospitals, Medical School of Sorbonne, Paris 6 : 3 missions, clinic/ treatments cancer, teaching, and research
2011 - 2017    Teacher and tutor for medical students to prepare the final national exam 
2010 – 2015   Residency of radiation oncology in the university hospital of Poitiers, Lausanne,  
2003 – 2010   Medical student of the University of Paris 5
2005 – 2007   Tutor of the medical entrance exam in Paris 5
 

04/2016           Swiss medical diploma and radiation oncology (recognize qualification)
11/2016           French medical complementary diploma in medical oncology
11/2017           University diploma, Paris 6, medical treatment of cancer
11/2016           University diploma, Paris 6, stereotactic radiotherapy
11/2015           French medical specialty diploma: radiation oncology
09/2015           University diploma, Gustave Roussy in head and neck cancers
09/2014           University diploma Nice, in high technicity radiotherapy, stereotactic technics, IMRT
12/2013           Specialist Thesis of a medical doctor in radiation oncology with distinctions
2012 – 2013   Master of science: cancer genesis, pharmacology anti-cancer

 

• Experiences in radiation oncology: Volumetric arc therapy and stereotactic,
• Languages: Fluent English, Fluent French, Spanish, Russian
• Skills: empathy, listening, teamwork,  flexibility, adaptability, analytical research, writing articles, teaching 
• Activities: running, tennis, swimming (competition level), surf, hobbies: travels    

• Oral communication 2018 for the French medical radiation oncology course
• Oral communication award of the French Society of radiation oncology, radio-physics 2014: IMRT techniques (modulated volume arc-therapy), advantages, disadvantages, clinical impact 
• Oral communication award of the French Society of radiation oncology, cancerology Monaco Congress 2014 
• Publications :

1. Advances in the management of cervical lymphadenopathies of unknown primary with intensity-modulated radiotherapy: Doses and target volumes. Cancer Radiother. 2018 May 3. pii: S1278-3218(18)30051-9. doi: 10.1016/j.canrad.2017.10.008.
2. Advances in the management of cervical lymphadenopathies of unknown primary: advances in diagnostic imaging and surgical modalities and new international staging system. Bull Cancer. 2018 Feb;105(2):181-192. doi: 10.1016/j.bulcan.2017.11.009. Epub 2017 Dec 21.
3. Quality and safety policy implementation for a new radiotherapy device. submitted to cancer radiotherapy 2018
4. From bunker construction to patient treatment: quality controls applied to modern radiotherapy techniques submitted to cancer radiotherapy 2018
5. Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy: a critical review of the literature, being submitted to a critical review of oncology
6. Chemoradiation for esophageal cancer: a critical review of the literature submitted to cancer radiotherapy 2018
7. GORTEC clinical practice guidelines for the delineation of nodal target volumes in intensity modulated radiation therapy for head and neck cancers in submission in radiation oncology
8. [Clinical research for rectal carcinoma: State of the art and objectives]. Cancer Radiother. 2017 Sep 7. pii: S1278-3218(17)30202-0. doi: 10.1016/j.canrad.2017.07.019. [Epub ahead of print] French.
9. [Lung dose constraints for normo-fractionated radiotherapy and for stereotactic body radiation therapy]. Cancer Radiother. 2017 Sep 5. pii: S1278-3218(17)30344-X. doi: 10.1016/j.canrad.2017.07.046. [Epub ahead of print] French.
10. Low level Laser therapy : a corner stone in the management of cancer therapy-Induced mucsitis Chapter 41 Handbook of low-level Laser therapy, 2017 Pan Stanford Publishing
11. Adaptive radiation therapy in head and neck cancer for clinical practice: state of the art and practical challenges. Jpn J Radiol. 2017 Feb;35(2):43-52. doi: 10.1007/s11604-016-0604-9.
12. Role of irradiation for patients over 80 years old with glioblastoma: a retrospective cohort study. J Neurooncol. 2016 Sep;129(2):347-53. doi: 10.1007/s11060-016-2182-1. Epub 2016 Jun 16.
13. Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients. Acta Oncol. 2016 Jun;55(6):767-73. doi: 10.3109/0284186X.2015.1120886. Epub 2016 Apr 1.
14. [Clinical and paraclinical follow-up after radiotherapy for head and neck cancer]. Cancer Radiother. 2015 Oct;19(6-7):597-602. doi: 10.1016/j.canrad.2015.05.017. Epub 2015 Aug 13. French.
15. [Mucosal melanomas of the head and neck: State of the art and current controversies]. Bull Cancer. 2015 Jun;102(6):559-67. doi: 10.1016/j.bulcan.2015.04.013. Epub 2015 May 26. French.
16. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].Cancer Radiother. 2015 Apr;19(2):127-38. doi: 10.1016/j.canrad.2014.12.005. Epub 2015 Mar 12. French.
17. [Lymph node metastases from squamous cell carcinoma of unknown primary site. Is it time to change of paradigm?]. Hamoir M, Troussier I, Machiels JP, Reychler H, Schmitz S, Thariat J, Grégoire V. Bull Cancer. 2014 May 1;101(5):455-60. doi: 10.1684/bdc.2014.1965. Review. French.
18. Cervical node of unknown primary: patterns of care and factors influencing the choice of clinical target volumes. Oral Oncol. 2014 May;50(5):e25-6.
19. [Target volumes in cervical lympadenopathies of unknown primary: toward a selective customized approach? On behalf of REFCOR]. Cancer Radiother. 2013 Nov;17(7):686-94. doi: 10.1016/j.canrad.2013.07.132. Epub 2013 Oct 4. Review. French.

• Posters :

1. Uni or bilateral irradiation in cervical lymph node metastases of unknown primary? Electronic Poster : MO_41_2858, ASTRO 2018 
2. Should neoadjuvant chemo-radiotherapy for esophageal cancers be adapted to histology? Literature Data Analysis, Poster SFRO 2018
3. Chemo-radiotherapy of pancreatic cancers: why and how to protect the spleen. Poster SFRO, October 2018
4. Uni. or bilateral irradiation of cervical lymph node metastases of unknown primary?

Oral Communication Submission, SFRO, October 2018

5. Immune checkpoint inhibitors and stereotactic radiosurgery (SRS) in melanoma brain metastases. ASCO online publication 2018, abstract 225009
6. The proposition of splenic dose-volume constraints to prevent severe lymphopenia after chemoradiation for pancreatic cancer. Astro 2018
7. Indications for external beam radiotherapy in differentiated thyroid carcinoma: an expert consensus – ESTRO 2018
8. Contemporary esophageal cancer management by chemoradiation: a survey of French radiation oncologists – ESTRO 2018
9. Whole brain radiotherapy and concurrent temozolomide in multifocal and/or multicentric newly diagnosed glioblastoma –  ESTRO 2018
10. 894P - A retrospective study of the management of metastatic renal cell carcinoma brain tumors Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371
11. Comparison of clinical target volumes between Phase III trials of exclusive chemoradiotherapy for esophageal cancers Cancer/Radiothérapie, Volume 21, Issues 6–7, Poster October 2017, Pages 695-696,
12. Management of patients with esophageal cancer by chemoradiotherapy: national multicentre practice survey, Cancer/Radiotherapy, Volume 21, Issues 6, 7 Poster SFRO October 2017, Page 681
13. Mono-isocentric conformational art therapy for multiple brain metastases: automated planning and a dosimetric comparison with Gammaknife® Perfexion™ Volume 21, Issues 6–7, Poster SFRO October 2017, Pages 685-686
14. Role of the manipulator in medical quality electroradiology in the implementation of modulated volumetric arcthérapie in a radiotherapy department, Cancer/Radiothérapie, Volume 19, Issues 6–7, Poster SFRO, October 2015, Pages 694
15. Focal dose escalation on the tumor index by associated high dose rate brachytherapy and three-dimensional conformational radiotherapy. Cancer/Radiothérapie, Volume 19, Issues 6–7, Poster SFRO, October 2015, Pages 671-672

Localized, intermediate or high-risk prostate cancer whose treatment was external radiation therapy and included high dose rate brachytherapy: Cancer/Radiothérapie, Volume 18, Issues 5–6, Poster SFRO October 2014, Page 622